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Objective: In this retrospective study, we clarified the impact of
smoking on prognosis and the association of clinicopathological
factors, particularly histologic subtype, in patients with small ade-
nocarcinoma of the lung.
Methods: Between 1996 and December 2006, 121 patients present-
ing with adenocarcinomas that had a diameter 2 cm were ana-
lyzed. The clinicopathological records of the patients were examined
for age, gender, nodal status (c-N and p-N), tumor size, serum
carcinoembryonic antigen level, histologic subtype, and smoking
history. A histologic subtype was defined using a modified World
Health Organization classification. These subtypes are bronchioloal-
veolar carcinoma (BAC), adenocarcinoma with little or no BAC
component (Non or min BAC), and mixed bronchioloalveolar car-
cinoma with other adenocarcinoma components.
Results: The overall 5-year survival rates were 94.4% for never-
smokers (N  55) and 79.2% for smokers (N  66) (p  0.05).
Cancer-specific 5-year survival rates were 98.0% for never-smokers
and 80.4% for smokers (p  0.03). Gender, serum carcinoembry-
onic antigen level, and histologic subtype were significantly associ-
ated with smoking status. Histologic subtype (Non or min BAC) was
the only significant prognostic factor in multivariate analyses. The
prevalence of smoking by histologic subtype was 27.3% for BAC,
43.2% for mixed bronchioloalveolar carcinoma, and 74.6% for Non
or min BAC. The prevalence was significantly higher in Non or min
BAC than in the others. Furthermore, the smoking index (daily ciga-
rette consumption times years of smoking) was significantly higher in
Non or min BAC than in the other two subtypes. In addition, patients
with a high smoking index showed a greater percentage of Non or min
BAC subtypes. Finally, male gender was associated with Non or min
BAC independent of smoking status (p  0.03).
Conclusions:When adenocarcinomas were small (diameter2 cm)
cigarette smoking and male gender were associated with Non or min
BAC histologic subtypes, which are thought to have more aggres-
sive biologic features resulting in poorer outcome compared with
other subtypes.
Key Words: Smoking, Histologic subtype, Small adenocarcinoma,
Lung.
(J Thorac Oncol. 2008;3: 958–962)
It is well known that cigarette smoking strongly increasesthe risk of lung cancer. Adenocarcinoma of the lung, once
considered minimally related to cigarette smoking, has be-
come the most common type of lung cancer in the United
States and Japan. Accelerated increases in the incidence of
adenocarcinoma and less rapid increases in squamous cell
carcinoma of the lung have been reported among cigarette
smokers in recent decades.1–3 Furthermore, recent studies
have indicated that smokers show a significantly unfavorable
prognosis when compared with never-smokers with regard to
lung cancer, especially in early stages of adenocarcinoma.4,5
Thus, it is suggested that smoking is associated not only with
lung carcinogenesis, but also with prognosis in lung cancer.
However, it is not clear why smokers with lung cancer have
a poorer prognosis than never-smokers.
In addition to smoking, we have previously defined
several prognostic factors in the early stage of lung adeno-
carcinoma such as histologic subtype, carcinoembryonic an-
tigen (CEA) concentrations and tumor diameter.6–9 Of these,
histologic subtype [modification of World Health Organiza-
tion (WHO) classification] is the most important independent
prognostic factor in small adenocarcinomas. Adenocarci-
noma (2 cm) with few bronchioloalveolar carcinoma
(BAC) components (mainly acinar, papillary, and solid with
mucin production) showed poorer outcome than mixed ade-
nocarcinoma with BAC.6–11
In this retrospective study, we clarified the influence of
smoking on the prognosis and association of clinicopatholog-
ical factors, particularly histologic subtype, in patients with
small adenocarcinoma of the lung.
PATIENTS AND METHODS
This was a retrospective study and individual patients
were not identified. Therefore, for this study, our institutional
review board waived the requirement for patient consent.
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Between 1996 and December 2006, 728 patients un-
derwent surgical resection of primary lung cancer within our
department. Among these patients, 121 were diagnosed with
adenocarcinoma that had a diameter 2 cm. The diagnosis
was made by evaluation of the resected tissue. The subgroup
with small adenocarcinoma consisted of 62 females and 59
males, with ages ranging from 35 to 82 (median: 64) years.
The patient characteristics are summarized in Table 1. The
clinicopathological records of the patients were examined for
age, gender, nodal status (c-N and p-N), tumor size, serum
CEA level, histologic subtype, and patient smoking history.
Patients were classified into a smoking group and a never-
smoking group based on their history. The smoking group
included both current smokers and ex-smokers. Furthermore,
the amount of smoking was evaluated by the Brinkman index
[(BI): the number of cigarettes consumed per day multiplied
by the years of smoking]. A histologic subtype was defined
using modification of the WHO classification of adenocarci-
nomas as reported previously.9–12 Briefly, these subgroups
are BAC, adenocarcinoma with no or little BAC compo-
nent (Non or min BAC), and mixed BAC with other
adenocarcinoma components mixed bronchioloalveolar
carcinoma (MBAC). The Non or min BAC includes forms
classified by the WHO12 as acinar adenocarcinoma, papil-
lary adenocarcinoma and solid tumor with mucin produc-
tion, with little or no presence of BAC. The mixed BAC
(nearly equivalent to Noguchi’s type C or replacing type
adenocarcinoma) is a tumor with BAC comprising at least
90% of its margin, and is mixed BAC with other adeno-
carcinoma components, such as acinar, papillary, and mu-
cin-producing solid.
In all patients, preoperative staging was assessed ac-
cording to the tumor, node, metastasis (TNM) classification
of the International Union Against Cancer,13 using chest
computed tomography (CT), abdominal CT or ultrasonogra-
phy, brain CT or magnetic resonance imaging, and bone
scanning. Clinical mediastinal and hilar lymph node status
was considered positive if the results of the chest CT showed
that the shorter axis was longer than 1.0 cm. The follow-up
period ranged from 6 to 108 months (the median follow-up
for living patients was 40 months).
Statistical Analysis
The length of survival was defined as the interval
between surgery and any cause of death or the most recent
follow-up. The survival rates were calculated using the
Kaplan–Meier method. Univariate analyses were performed
using the log-rank test, 2 test, and analysis of variance
(ANOVA). Multivariate analyses were performed for vari-
ables demonstrating a p value 0.05 in univariate analysis,
using the logistic regression procedure test in StatView J 5.0
(SAS institute, Cary, North Carolina). A p value 0.05 was
treated as significant.
RESULTS
Postoperative Prognosis and
Clinicopathological Factors According to
Smoking Status (Table 2)
Prognosis
The overall 5-year survival rates were 94.4% for never-
smokers (N  55) and 79.2% for smokers (N  66) (p 
0.05). Cancer-specific 5-year survival rates were 98.0% for
never-smokers and 80.4% for smokers (p  0.03).
Clinicopathological Factors
Gender (male), serum CEA level (high CEA level), and
histologic subtype (Non or min BAC) were significantly
associated with smoking status (p  0.001, p  0.02, p 
0.001, respectively). However, age and tumor diameter were
not associated with smoking.
Prognostic Factors Determined by Multivariate
Analysis
Three factors (gender, serum CEA level, and histologic
subtype) were evaluated to determine if they are independent
prognostic factors along with smoking status using multivar-
iate analysis. We performed multivariate analyses using two
models; one model included BAC cases and the other ex-
cluded BAC cases, since these cases are defined as preinva-
sive lesions3 and are considered as a well-established inde-
pendent prognostic factor.
Among the four factors (the three factors and smoking
status), histologic subtype (Non or min BAC) was the only
significant prognostic factor in both of the multivariate mod-
TABLE 1. Patient Characteristics
Characteristics Value
Median age, yr (range) 64 (35–82)
Gender (male/female) 59/62
Tumor diameter (mm) 15.6  3.4
c-N (N0/N1/N2) 117/1/3
p-N (N0/N1/N2) 100/9/12
Histologic subtype (BAC/mixed BAC/non or minimal BAC) 22/44/55
Smoking status (smoker/never-smoker) 66/55
BAC, bronchioloalveolar carcinoma.
TABLE 2. Clinicopathological Factors According to
Smoking Status
Variables
Smokers
(N  66)
Never-Smokers
(N  55) p
5-yr survival (%)
Over all 79.2 94.4 0.05
Cancer-specific 80.4 98.0 0.03
Age 64.3  9.8 63.9  10.4 0.86
Gender
Male/female 50/16 9/46 0.001
Tumor diameter (mm) 15.9  3.6 15.2  3.3 0.3
CEA 3 ng/ml
cases (%)
36 (54.6%) 18 (32.8%) 0.02
Histologic subtype
Non or min BAC (%) 41 (62.1%) 14 (25.5%) 0.001
Non or min BAC, non or minimal bronchioloalveolar carcinoma; CEA, carcino-
embryonic antigen.
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els (Table 3). Gender and CEA level in addition to smoking
status were not significant independent prognostic factors in
multivariate analyses when they were analyzed along with
histologic subtype.
Association Between Histologic Subtype and
Smoking Status
Because smoking status was not a significant indepen-
dent prognostic factor in small adenocarcinoma, we exam-
ined the association between smoking status and histologic
subtype (an independent prognostic factor). The prevalence
of smoking by histologic subtype was 27.3% for BAC, 43.2%
for MBAC, and 74.6% for Non or mini-BAC. The smoking
prevalence was significantly higher in patients with Non or
mini-BAC subtype than in the others (versus BAC: p  0.04,
versus MBAC: p  0.001, respectively). There was no
difference in the smoking prevalence between the BAC and
MBAC subtypes (Figure 1). The BIs by histologic subtype
were 333  596 for the BAC, 232  387 for the MBAC, and
785  734 for the Non or mini-BAC. BI was significantly
higher for Non or mini-BAC subtype than for the other two
subtypes (versus BAC: p  0.04, versus MBAC: p  0.001,
respectively) (Figure 2). Furthermore, the percentages of the
three histologic subtypes for BI are summarized in Figure 3.
An elevated BI occurred in a high percentage of Non or
mini-BAC subtype. The percentage of Non or mini-BAC was
23.6% in never-smokers, 48.8% in low BI patients (range,
1–1000), and 64.0% in high BI patients (over 1000) (p 
0.001).
CEA, Gender, and Histologic Subtype
Analysis was carried out to determine a possible cor-
relation of CEA concentration and gender with histologic
subtype. The percentage of BAC, MBAC, and Non or mini-
BAC subtype in high CEA patients was 22.7 (5/22), 26.0
(13/50), and 73.5% (36/49), respectively. In high CEA
patients, the percentage of Non or mini-BAC subtype was
significantly higher than that of the other subtypes (versus
BAC: p  0.001, versus MBAC: p  0.001, respectively),
whereas the percentage of BAC and MBAC subtypes was
similar. About 72.3% (16/22) of tumors with BAC, 62.0%
(31/50) with MBAC, and 30.6% (15/49) with the Non or
mini-BAC subtypes occurred in females. The percentage
of the Non or mini-BAC subtype was significantly higher
than that of the others (versus BAC: p  0.002, versus
MBAC: p  0.002, respectively). Finally, we examined
smoking status and gender to determine any association
with Non or mini-BAC subtype in multivariate analysis
(Table 4). Both factors (smoker and male gender) were
associated with Non or mini-BAC independently (p  0.03
for each factor).
TABLE 3. Prognostic Factors, Multivariate Analysis
Including Cases with BAC and Excluding Cases with BAC
Variables Odds Ratio 95% CI p
Including cases
Smoking
Non smoker 0.5 0.1–2.4 0.38
Gender
Female 1.2 0.3–5.2 0.81
CEA 3 ng/ml 1.7 0.4–6.5 0.45
Histologic subtype
Non or min-BAC 12.5 1.4–111.1 0.02
Excluding cases
Smoking
Non smoker 0.5 0.1–2.5 0.40
Gender
Female 1.2 0.3–5.1 0.82
CEA 3 ng/ml 1.7 0.4–6.5 0.45
Histologic subtype
Non or min-BAC 9.3 1.1–83.3 0.04
CI, confidence interval; non or min-BAC, non or minimal bronchioloalveolar
carcinoma; CEA, carcinoembryonic antigen.
FIGURE 1. Histologic subtype and smoking status. *p 
0.004 when compared with BAC. **p  0.001 when com-
pared with MBAC. BAC: bronchioloalveolar carcinoma.
MBAC: mixed bronchioloalveolar carcinoma. N/MnBAC: non
or minimal bronchioloalveolar carcinoma.
FIGURE 2. Histologic subtype and Brinkman index. *p 
0.004 when compared with BAC. **p  0.001 when com-
pared with MBAC. BAC: bronchioloalveolar carcinoma.
MBAC: mixed bronchioloalveolar carcinoma. N/MnBAC: non
or minimal bronchioloalveolar carcinoma.
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CONCLUSIONS
In this study, we found that the postoperative prognosis
(calculated using cancer-specific mortality) was poorer in
smokers than in never-smokers among patients with small
adenocarcinoma of the lung. However, smoking status was
not a significant independent prognostic factor in multivariate
analyses when examined together with gender, CEA concen-
tration and histologic subtype. The histologic subtype (Non
or minimal BAC) was the only independent prognostic factor
with or without BAC models in patients with small adeno-
carcinoma. Furthermore, smoking status was associated
with the histologic subtype: smokers showed significantly
increased ratios of Non or min BAC than other subtypes
(BAC or mixed BAC). In addition, the ratio of Non or min
BAC was significantly higher in the higher BI group than
in the lower BI group. This suggests that cigarette smoking
is associated with carcinogenesis of Non or min BAC type
adenocarcinoma (papillary, acinar, or solid with mucin
production type), which is thought to have much more
aggressive biologic features resulting in poor prognosis
compared with those of the mixed BAC type, when the
tumor diameter is 2 cm.6,9,10,12,14,15
Small peripheral adenocarcinomas can be classified
into subgroups according to tumor growth patterns, which are
thought to be associated with the tumor’s biologic character-
istics derived from clinicopathological examination.9,10,14,15
These subgroups are BAC (noninvasive cancer), adenocarci-
noma with little or no BAC component (defined as Non or
min BAC in this study), and mixed BAC with other adeno-
carcinoma components (mixed BAC), such as acinar, papil-
lary, and mucin-producing solid tumors. We have already
reported that the minimal or non BAC type demonstrated a
vessel invasion rate of nearly 90% (versus 26% in mixed
BAC type) and a lymph node involvement rate of 32% (27%
even in cN0, versus 3% in mixed BAC type), and reported
that this type was also an adverse independent prognostic
factor in small adenocarcinoma.6,12 Similarly, the lesion sub-
type reflects the biologic characteristics of the tumor better
than the lesion size for small lung adenocarcinoma. Noguchi
et al. 10,11 reported that lymph node involvement appeared in
22.4% of mixed BAC type versus 41.1% of minimal or non
BAC types, and that mitotic figures were more often observed
in the minimal or non BAC type than in the mixed BAC type.
Male gender and a history of smoking were reported to
be adverse prognostic factors in stage I non-small cell lung
cancer (NSCLC); however, the mechanisms by which gender
and smoking affect the prognosis of lung cancer patients were
not clear.16 The observation that gender and smoking status
are associated with histologic subtype in the present study
may explain the mechanism in part. That is, male gender and
smoking were closely associated with adenocarcinoma hav-
ing Non or mini-BAC features. Furthermore, serum CEA has
been reported to be a prognostic factor in early stage lung
cancer,6–8 although high serum CEA was found not to be an
independent prognostic factor in small adenocarcinoma. It is
suggested that high serum CEA is associated with the Non or
mini-BAC histologic subtype resulting in poor outcome.
Toyooka et al.17 indicated that methylation rates of
some important tumor suppressor genes such as APC and P16
were significantly higher in smokers compared with never-
smokers. Tanaka et al.18 demonstrated that aberrant methyl-
ation of the promoter region of the p16 gene and its loss of
expression were associated with smoking status (the group
with BI600 showed a higher rate of loss of expression than
in group with BI 600), and that the genetic alterations were
closely associated with poor prognosis in small adenocarci-
noma of the lung. They also showed that the rates of p16
expression loss were 20% in BAC, 54.2% in mixed BAC
(Noguchi type C) and 72.2% in Non or min BAC (Noguchi
type D, E, F). According to these findings, it is suggested that
cigarette smoking is one of the most important risk factors for
some genetic alterations such as loss of p16 expression,
which may be associated with the development of Non or min
BAC adenocarcinoma. Recently, it was reported that the
EGFR and HER2 mutation was mainly found in never-
smokers, whereas the KRAS mutation was found mostly in
smokers or former smokers.19 However, the association be-
tween smoking status and features both in histologic pheno-
type and genotype is still unclear, and additional studies are
necessary to clarify this issue.
In conclusion, cigarette smoking and male gender were
associated with Non or min BAC type adenocarcinoma (pap-
illary, acinar, or solid with mucin production type), which is
considered to have much more aggressive biologic features
that lead to a poor prognosis compared with those of other
types, when the tumor diameter is 2 cm. The limitations of
FIGURE 3. Brinkman Index and histologic subtype. BAC:
bronchioloalveolar carcinoma. MBAC: mixed bronchioloal-
veolar carcinoma. N/MnBAC: non or minimal bronchioloal-
veolar carcinoma.
TABLE 4. Risk Factors for Non or Min BAC
Variables Odds Ratio 95% CI p
Smoking
Smoker 2.7 1.08–6.93 0.03
Gender
Male 2.8 1.12–6.94 0.03
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this study include the retrospective nature of the analysis,
the small sample size, and a few instances of tumor
diameter 10 mm.
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